entertainment -WSS

entertainment

author：explore 2025-09-27 13:09:54 - browse：21

Adam's take main illustration — Molly Ferguson/STAT

Anavex Life Sciences is in a tough spot. The serial dissembler of clinical trial results might be forced, finally, to tell the truth when it reads out its next study in Rett syndrome.

What sets Anavex apart from all the other biotechs on my radar screen is its habit of shifting the goalposts on clinical trials. Twice last year, first in February and then in December, Anavex announced “positive” outcomes from studies of its drug called blarcamesine — except the results were derived from efficacy endpoints that were not part of the original study designs.

If blarcamesine fails to achieve the pre-determined goals of clinical trials, the thinking apparently goes, then just make a post-hoc change to the study goals.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： House GOP plan to stem drug shortages differs from Democrats’

WSS

Private equity could exacerbate cardiology's overuse problem, experts fear

5 wounded, 2 critically, in Michigan shopping center shooting

9 mass shootings over the weekend rock US cities, leaving 5 dead, 56 injured

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

How housing is health care on Long Island

Young Chinese opt out of the rat race and pressures at home to pursue global nomad lifestyle

entertainment

entertainment

hotspot

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

New weight loss drugs vying to be the next Wegovy or Mounjaro

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

PEPFAR is under serious threat — and so is global health

Activists slam private health insurers over coverage restrictions

Will the IRA bring competition to the biologics market?

In age of alternative facts, a scholarly course on calling out crap

FDA approves updated Covid vaccines

Psychedelics group wrestles with new pharma identity

What AstraZeneca

focus

Fla. should 'correct' controversial slavery curriculum: Republican Rep. Byron Donalds

Doctors increasingly discourage vaping amid mounting health concerns

Pig kidney works a record two months in donated body

Long Covid needs a new name — and a new frame

How housing is health care on Long Island

FDA proposes changes to key medical devices approval pathway

Wikipedia

Wikipedia

knowledge

entertainment